2020 has been a hectic deal-making year for the biopharmaceutical industry, with the most significant deals – Gilead Sciences, Inc./Immunomedics, Inc. and Merck & Co., Inc./Seattle Genetics, Inc. – occurring in recent days, despite the ongoing COVID-19 pandemic. Deal-making in cancer has been particularly voluminous, continuing the trend of recent years. In this infographic, we mine information from Scrip coverage from the and the Biomedtracker database to provide a snapshot of the year’s cancer deal-making as of mid-September – highlighting the most significant acquisitions and alliances, gathering in one place the highest-value transactions, and also depicting which companies were most active and what development stages and therapeutic modalities saw the greatest activity.
To download this infographic, click here.
